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Objectives The purpose of this study was to compare the early and late results of percutaneous and surgical revasculariza-
tion of left main coronary artery stenosis.
Background Unprotected left main coronary artery (ULMCA) stenting is being investigated as an alternative to bypass surgery.
Methods We randomly assigned 105 patients with ULMCA stenosis to percutaneous coronary intervention (PCI; 52 pa-
tients) or coronary artery bypass grafting (CABG; 53 patients). The primary end point was the change in left ven-
tricular ejection fraction (LVEF) 12 months after the intervention. Secondary end points included 30-day major
adverse events (MAE), major adverse cardiac and cerebrovascular events (MACCE), length of hospitalization, tar-
get vessel failure (TVF), angina severity and exercise tolerance after 1 year, and total and MACCE-free survival.
Results A significant increase in LVEF at the 12-month follow-up was noted only in the PCI group (3.3  6.7% after PCI
vs. 0.5  0.8% after CABG; p  0.047). Patients performed equally well on stress tests, and angina status im-
proved similarly in the 2 groups. PCI was associated with a lower 30-day risk of MAE (p  0.006) and MACCE
(p  0.03) and shorter hospitalizations (p  0.0007). Total and MACCE-free 1-year survival was comparable.
Left main TVF was similar in the 2 groups. During the 28.0  9.9-month follow-up, there were 3 deaths in the
PCI group and 7 deaths in the CABG group (p  0.08).
Conclusions Patients with ULMCA disease treated with PCI had favorable early outcomes in comparison with the CABG group.
At 1 year, LVEF had improved significantly only in the PCI group. After more than 2 years, MACCE-free survival was
similar in both groups with a trend toward improved survival after PCI. (Study of Unprotected Left Main Stenting
Versus Bypass Surgery [LE MANS study]; NCT00375063). (J Am Coll Cardiol 2008;51:538–45) © 2008 by
the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.09.054g
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ror more than 2 decades after the advent of coronary
ngioplasty, left main percutaneous coronary intervention
PCI) was not considered to be a viable alternative to
oronary artery bypass grafting (CABG). The unpredictable
ccurrence of abrupt closure or restenosis put patients under-
oing unprotected left main coronary artery (ULMCA) an-
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inistry of Science and Informatics (grant 4P05B00819).t
Manuscript received March 21, 2007; revised manuscript received September 10,
007, accepted September 17, 2007.ioplasty at risk of severe perioperative complications and
ate sudden death. The advent of coronary stents dramati-
ally lowered the incidence of abrupt vessel closure, and the
pplication of drug-eluting stents (DES) decreased the risk
f ULMCA in-stent restenosis (1–4). Additionally, the
estoration of native, antegrade flow through the left main
oronary artery (LMCA) may have an advantage over
onventional bypass surgery (5).
Several investigators have reported the safety and
easibility of unprotected left main stenting with bare-
etal stents (BMS) (6 –11). Promising long-term results
ave been reported with both BMS and DES in a limited
eries of publications (1– 4,12,13). In our nonrandomized
egistry, we observed improvements in left ventricular func-
ion following PCI for ULMCA disease (14). Thus far, there
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February 5, 2008:538–45 The LE MANS Prospective Randomized Studyas not been a prospective randomized trial comparing the
hort- and long-term results of unprotected left main
tenting with CABG. Additionally, it is not clear whether
he method of revascularization affects left ventricular (LV)
unction in patients with left main stenosis.
Therefore, the purpose of the present study was to
ompare acute and late clinical end points, functional status,
nd LV function at 1 year following stent-supported PCI or
ABG for ULMCA disease in a prospective randomized
rial.
aterials and Methods
e enrolled 105 patients with 50% narrowing of UL-
CA, with or without multivessel coronary artery disease
uitable for equal revascularization both with PCI and
ABG. All patients had to be symptomatic with docu-
ented myocardial ischemia. Exclusion criteria included
cute myocardial infarction, total occlusion of left main,
omorbid conditions, or coronary anatomic considerations
hat increased the surgical risk to a Euroscore of 8 or more,
troke or transient ischemic attack within 3 months, renal
ysfunction, or contraindication to antiplatelet therapy.
Three hundred forty-seven consecutive patients with
ore than 50% left main stenosis were screened between
001 and 2004. Based on a joint decision by the lead
nterventional and surgical investigators, 122 patients
ere suitable for both procedures; 105 gave consent and
ere randomized to either PCI (n  52) or CABG (n 
3) (Fig. 1). Both groups were comparable with regard to
asic clinical and angiographic data (Table 1). All ran-
omized patients underwent their assigned therapy (no
All patients treated according to 
randomization (no crossovers)
Number of patients screened with UPLM disease:
347
Patients eligible for study:
122
Patients noneligible for study
included in LE MANS Registry:
225
PCI
102
CABG
123
Randomized patients:
105
Nonrandomized patients:
17
PCI
9
PCI
52
CABG
8
CABG
53
Figure 1 Experimental Design of the Study
Three hundred and forty-seven patients with unprotected left main (UPLM)
disease were screened. Patients who were eligible for the study and signed
informed consent (105 patients) were randomized to both treatment arms. Sev-
enteen patients were not randomized due to their refusal. Patients not eligible
for the study were included in the LE MANS registry. CABG  coronary artery
bypass grafting; PCI  percutaneous coronary intervention.rossovers). dThe LV function was evalu-
ted by 2-dimensional echocar-
iography before and 12 months
fter the index procedure. Tread-
ill stress tests were performed
t 1, 3, 6, and 12 months after
he procedure. Patients in the
CI group underwent a follow-
p angiography within 4 to 6
onths. Major adverse cardiac and
erebrovascular events (MACCE)
nd other major adverse events
MAE) were recorded during the
ntire follow-up period up to 5
ears.
ercutaneous revasculariza-
ion. Direct stenting of the left
ain was a preferred strategy
xcept for cases with critical lu-
inal narrowing, for which
redilatation was performed with
mall balloons (2.0 to 2.5 mm).
or distal left main stenosis, stenting across the bifurcation
oward the left anterior descending was performed first, and
hen provisional stenting of the circumflex artery with
-stenting or “culotte” technique was preferred. The crush
tent technique was avoided. Post-dilation with kissing
alloon angioplasty was always used to finish the distal left
ain stenting procedure. Drug-eluting stents were used for
he left main with a reference diameter of 3.8 mm, and
MS were implanted if the left main reference diameter was
.8 mm or greater. Based on these criteria, the left main was
reated with DES in 35% of PCI patients. Stent length and
iameter were selected on the basis of online quantitative
oronary angiography (balloon to artery ratio 1:1.1) and
ost-dilated at high pressure (at least 16 atmospheres). A
ontrol intravascular ultrasound was recommended to assess
he final results.
Intra-aortic balloon contrapulsation and percutaneous
ardiopulmonary support were used only in the subgroup of
atients with complex stenotic lesions in coronary vessels
upplying more than 50% of the viable myocardium coex-
sting with significantly depressed LV function (left ventric-
lar ejection fraction [LVEF] 25%). Therapy with acetyl-
alicylic acid and a thienopyridine (clopidogrel or
iclopidine) was initiated at least 2 days before the proce-
ure. Intravenous glycoprotein IIb/IIIa blockers were used
t the operator’s discretion only in procedures performed in
atients with complex coronary lesions and unstable angina.
nfractionated heparin was used in standard doses. Angio-
raphic success was defined as left main residual stenosis
30%, minimal lumen diameter at least 3 mm, Thrombol-
sis In Myocardial Infarction flow grade 3, and no dissec-
ion. Clinical success included angiographic success and no
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CABG  coronary artery
bypass grafting
DES  drug-eluting stent(s)
LVEF  left ventricular
ejection fraction
MACCE  major adverse
cardiac and
cerebrovascular events
MAE  major adverse
events
PCI  percutaneous
coronary intervention
TVF  target vessel failure
TVR  target vessel
revascularization
ULMCA  unprotected left
main coronary arteryeath or myocardial infarction in-hospital outcome.
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The LE MANS Prospective Randomized Study February 5, 2008:538–45urgical revascularization. Operations were performed
sing standard anesthetic techniques. All but 1 operation
ere performed through a median sternotomy, with stan-
ard cardiopulmonary bypass and moderate systemic hypo-
hermia. One patient underwent off-pump CABG. Left
nternal mammary artery grafts were used in 72% of CABG
atients, and radial artery grafts were used in 9%.
harmacologic treatment after revascularization. All pa-
ients stayed on double antiplatelet treatment for at least 12
onths. Other pharmacological treatments (e.g., statins,
ngiotensin-converting enzyme inhibitors, beta-blockers)
ere recommended based on current practice and were left
o the discretion of a supervising physician.
rimary end point. The change in LVEF assessed by
-dimensional echocardiography 12 months after the
ndex intervention was the primary end point of this
tudy.
econdary end points. Secondary end points included
0-day and 1-year MAE and MACCE, length of hospital-
aseline Characteristics of the Study Groups
Table 1 Baseline Characteristics of the Study Groups
Variables
PCI
(n  52)
CABG
(n  53) p Value
Age (yrs) 60.6 10.5 61.3 8.4 0.69
Male (%) 60 73 0.13
CCS class 3.1 1.0 2.8 1.0 0.17
LVEF (%) 53.5 10.7 53.7 6.7 0.86
LVEF 50% (%) 21 17 0.58
DM (%) 19 17 0.80
Hypertension (%) 75 70 0.78
Hypercholesterolemia (%) 65 60 0.78
Previous myocardial infarction
STEMI (%) 25 21 0.60
NSTEMI (%) 11 11 0.97
Euroscore 3.3 2.3 3.5 2.3 0.65
Distal LM disease (%) 56 60 0.63
No. of diseased vessels 1.7 0.93 2.08 0.83 0.33
1-vessel disease (%) 13 6 0.17
2-vessel disease (%) 27 19 0.32
3-vessel disease (%) 60 75 0.08
Syntax score 25.2 8.7 24.7 6.8 0.75
QCA baseline
Proximal reference diameter
(mm)
3.6 0.9 3.8 1.1 0.38
Distal reference diameter
(mm)
3.4 0.9 3.7 1.0 0.47
Minimal lumen diameter
(mm)
1.4 0.6 1.5 0.5 0.46
Percent diameter stenosis (%) 60 12 60 13 0.91
DES/arterial graft to LAD (%) 35 81 —
Dilated arteries/no. of grafts 2.3 0.8 2.9 0.8 0.006
Complete revascularization (%) 79 89 0.17
Hospitalization (days) 6.8 3.7 12.04 9.6 0.0007
alues are mean  SD or %.
CABG  coronary artery bypass grafting; CCS  Canadian Cardiovascular Society; DES 
rug-eluting stent; DM  diabetes mellitus; LAD  left anterior descending; LIMA  left internal
ammary artery; LM  left main; LVEF  left ventricular ejection fraction; PCI  percutaneous
oronary intervention; QCA  quantitative coronary angiography; STEMI  ST-segment elevation
yocardial infarction; NSTEMI  non–ST-segment elevation myocardial infarction.zation, exercise tolerance measured with an electrocardio- 3raphic treadmill stress test along with angina severity
ccording to the Canadian Cardiovascular Society classifi-
ation after 1 year, total survival and freedom from
ACCE, and target vessel failure (TVF) and revascular-
zation (TVR).
The MAE were defined as all-cause mortality, acute
yocardial infarction (defined as an increase in creatine
hosphokinase (CPK)-MB to higher than 3 times the upper
imit of normal after PCI and 5 times after CABG), repeat
evascularization, acute heart failure (e.g., pulmonary
dema, cardiogenic shock), or low output syndrome requir-
ng intravenous inotropic agents and/or intra-aortic balloon
ump support, post-procedural complications leading to
eintervention, stroke, arrhythmia (ventricular fibrillation,
entricular tachycardia, or atrial fibrillation), major bleeding
equiring additional blood transfusion, and infections com-
romising post-procedural rehabilitation. Any cardiac mor-
ality, acute myocardial infarction, stroke, repeat interven-
ion, and/or acute/subacute in-stent thrombosis were
onsidered MACCE. Target vessel failure was defined as
ny MACCE related to insufficient flow through the
MCA, and TVR as any repeat intervention (PCI or
ABG) caused by a narrowing of the LMCA. The inci-
ence of stent thrombosis was evaluated in accordance with
he Academic Research Consortium Definitions of Stent
hrombosis (15).
All clinical outcomes were analyzed by the Clinical Event
ommittee. Echocardiographic and stress test recordings
ere read centrally by a group of independent investigators
naware of treatment assignment. Left ventricular ejection
raction was assessed according to the recommendations of
he American Society of Echocardiography, based on
he Simpson method of LV volume measurement and
econd harmonic imaging (Sonos 7500, Phillips Medical
ystems, Andover, Massachusetts) (16). Reproducibility for
-dimensional echocardiography recordings and measure-
ents of LVEF calculated as a coefficient of variance ranged
etween 3.6% and 4.0%.
The treadmill stress test was performed using the Cornell
rotocol (17) and evaluated according to ACC/AHA guide-
ines (18).
The 12-lead electrocardiography and CPK/CPK-MB
evels were checked every 12 h during the first 3 days after
he procedure and then subsequently in cases of myocardial
schemia (prolonged chest pain and/or electrocardiographic
hanges).
afety and ethics. The study protocol and written in-
ormed consent were approved by the Ethics Committee at
he Medical University of Silesia. Percutaneous coronary
ntervention procedures were carried out by experienced
nterventional cardiology teams in high-volume centers
2,500 to 4,700 PCI procedures per year) with cardiac
urgery backups on site. Surgery was carried out by experi-
nced cardiac surgery teams (performing 2,000 to 3,000
ABG procedures per year with mortality rates of 2% to
%).
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February 5, 2008:538–45 The LE MANS Prospective Randomized Studytatistical analysis. All analyses were performed according
o the intention-to-treat principle. The data with paramet-
ic distribution were expressed as means  standard devia-
ions, whereas nonparametric data were expressed as abso-
ute numbers  percentage. Moreover, 95% confidence
ntervals (CIs) and relative risk (RR) for results of the
rimary end point and selected secondary end points were
alculated.
The parametric variables between the groups were com-
ared using the unpaired Student t test. The 2-way analysis
f variance (ANOVA) and Newman-Keuls tests were used
or comparison of the parametric data between and within
he 2 groups at different time points if the Shapiro-Wilk test
howed normal distribution of variables and the Levene test
howed homogeneity of variances. For parametric data not
ulfilling the above criteria, the Wilcoxon test was used to
ompare the variables within the group at different time
oints and the Mann-Whitney U test to compare variables
etween the groups at the same time points. The ANOVA
riedman test was used to compare rank variables of
ifferent time points and the Mann-Whitney U test to
ompare variables between the groups at the same time
oints.
The chi-square test or Fisher exact test was used for
omparison of nonparametric variables. Survival curves were
rawn using Kaplan-Meier analysis. The F-Cox test was
sed for comparison of the survival curves between the
reatment arms.
The number of patients in both treatment groups was
stablished based on prior observations (14) that differences
n LVEF of more than 5% from the base value would be
ignificant and detected with p 0.05 and rejected with the
ower of the test 90%. The calculations were performed
or the paired t, ANOVA, and Wilcoxon tests to make sure
etailed List of MAE in CABG and PCI Group During the First Year
Table 2 Detailed List of MAE in CABG and PCI Group During th
CABG (n  53)
0 to 30 Days 1 to 12 Months
Death 2 2
Nonfatal myocardial infarction 2 1
Unstable angina 0 3
Major bleeding 3 0
Stroke 2 0
Acute heart failure 3 1
Repeat revascularization 0 5
PCI LM 0 2
Other vessel PCI 0 3
CABG 0 0
Renal insufficiency 1 0
Other (infection, post-cardiotomy
syndrome, sternal refixation)
7 1
Severe arrhythmia (VF, VT, AF) 3 2
Any MACCE 7† 6
Any MAE 15‡ 9
p  0.01. †p  0.03. ‡p  0.006.
AF  atrial fibrillation; MACCE  major adverse cardiac and cerebrovascular events; MAE  major ad
able 1.hat irrespective of the distribution of the observed values,
he study would obtain the relevant power of the test for its
rimary end point. Additionally, a delta between the
2-month and basic values of LVEF was calculated to
upport the significance of the observed changes above
-point scores between the groups with a power of
npaired t test 85%.
esults
arly outcome. Angiographic success was obtained in all
CI patients, and in-hospital clinical success was observed
n 98% of the patients in the PCI group and in 92% in the
ABG group (p  0.4). The patients assigned to CABG
aited longer for the index procedure: 14.0  27.1 days
median 4 days) prior to CABG versus 4.4  14.2 days
median 2 days) prior to PCI. There were no events during
his period.
Between the index procedure and 30 days later, there
ere no deaths in the PCI group and 2 deaths in the CABG
roup (p  0.16). PCI was associated with a significantly
ower risk of MAE (8% vs. 28%; 95% CI 0.64 to 0.94; RR
.78; p  0.006) and MACCE (2% vs. 13%; 95% CI 0.79
o 0.99, RR 0.88; p  0.03) and shorter hospitalizations
6.8  3.7 days vs. 12.0  9.6 days; p  0.0007) (Table 2).
significant reduction of angina severity (Canadian Car-
iovascular Society classification) after 1 month was ob-
erved in both groups (ANOVA Friedman test: p 0.001).
ate outcome. The LVEF values at baseline and after 12
onths are presented in Figure 2. The absolute change in
VEF (calculated as a delta) was significantly greater after
CI than after CABG (3.3  6.7%; 95% CI 1.3 to 5.3 vs.
.5  0.8%; 95% CI 1.4 to 2.5; p  0.047). One year after
the Procedure
st Year After the Procedure
PCI (n  52)
12 Months 0 to 30 Days 1 to 12 Months 0 to 12 Months
4 0 1 1
3 1 0 1
3 1 7 8
3 0 0 0
2 0 0 0
4 2 1 3
5* 1 14 15*
2 0 5 5
3 1 8 9
0 0 1 1
1 0 0 0
8 0 0 0
5 1 2 3
13 1† 15 16
24 4‡ 16 20After
e Fir
0 toverse events; VF  ventricular fibrillation; VT  ventricular tachycardia; other abbreviations as in
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The LE MANS Prospective Randomized Study February 5, 2008:538–45evascularization, LVEF was also significantly better in the
CI group (Mann-Whitney U test: p  0.01).
Post-procedure reduction of angina severity was main-
ained through 12 months of observation in both groups
Fig. 3). Patients after PCI had more angina after 6 months
Mann-Whitney U test: p  0.01) but had similar angina
tatus to CABG patients after 12 months (p  0.11).
Figure 2 LVEF in PCI and CABG Groups
at Baseline and After 12 Months
There was no significant difference in LVEF between the groups at baseline
(p  0.22). After 1 year, LVEF improved significantly in the PCI group (p 
0.04) but did not in the CABG group (p  0.85). There was a significant differ-
ence in LVEF between the groups after 12 months (p  0.01). CI  confidence
interval; LVEF  left ventricular ejection fraction; SD  standard deviation;
other abbreviations as in Figure 1.
Figure 3 CCS Functional Class at Baseline and Follow-Up
At the same time points, angina status based on Canadian Cardiovascular
Society (CCS) classification was maintained through 12 months of observation.
Patients after PCI had more angina after 1 month and after 6 months (Mann-
Whitney U test: p  0.01) but had similar rates of angina as CABG patients
after 12 months (p  0.11). ANOVA  analysis of variance; other abbrevia-
tions as in Figures 1 and 2.iPatients after PCI and CABG performed equally well on
readmill stress tests with the exception of the first month
ost-procedure, when patients after PCI performed better
Fig. 4).
Actuarial 1-year survival was comparable in both groups:
8.1% for PCI and 92.5% for CABG (p  0.37). During
8  9.9 months of follow up, there were 3 deaths in the
CI group (1 death during the first year) and 7 deaths in the
ABG group (4 deaths during the first year, including
n-hospital events). According to Kaplan-Meier analysis,
here was a trend toward better long-term survival after PCI
F-Cox test: p  0.08) (Fig. 5). The risk of MACCE and
AE in 12 months of observation was comparable in both
roups (RR 1.09, 95% CI 0.85 to 1.38 and RR 0.89, 95%
I 0.64 to 1.23 for MACCE and MAE, respectively). The
ACCE-free 1-year survival was nonsignificantly lower in
he PCI group compared with the CABG group (71.2% vs.
5.5%, respectively; p  0.29), and the difference was
ainly related to repeat revascularization (RR 1.27, 95% CI
.05 to 1.54; p  0.01) (Table 2). Similarly, long-term
ACCE-free survival did not differ significantly between
he groups (53.9% vs. 56.6%, respectively; F-Cox test: p 
.47) (Fig. 6).
The TVF was similar after CABG and PCI (9.4% vs.
.6%; p  0.97). Left main in-stent restenosis occurred in 5
atients (9.6%), including 1 restenosis in the DES subgroup
5.5%) and 4 in the BMS subgroup (11.7%). Four patients
ere successfully treated with repeat PCI; in 1 patient after
epeat PCI, a second restenosis occurred and CABG was
erformed (TVR, 9.6%).
Acute, subacute, and late stent thrombosis did not occur
Figure 4 Results of Treadmill
Stress Tests After PCI and CABG
Patients after PCI and CABG performed equally well on treadmill stress tests
with an exception of the first month post-procedure, when patients after PCI
performed better. METs  metabolic equivalents; other abbreviations as in
Figures 1 and 2.n the PCI group.
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February 5, 2008:538–45 The LE MANS Prospective Randomized Studyiscussion
he Left Main Stenting trial is the first prospective ran-
omized study comparing the outcome of PCI versus
ABG in patients with ULMCA disease.
Our study showed that there was a lower risk of 30-day
vents (MACCE and MAE) after PCI compared with
ABG. After 12 months, LVEF improved significantly
nly in the PCI group. Both groups demonstrated similar
mprovement in angina and good long-term functional
apacity on exercise stress testing. During the 28  9.9
onths of follow up, MACCE-free survival was compara-
Figure 6 MACCE-Free Survival After PCI and CABG
Long-term MACCE-free survival did not differ significantly between the groups
(53.9% vs. 56.6%, respectively; F-Cox test: p  0.47). MACCE  major adverse
cardiac and cerebrovascular events; other abbreviations as in Figure 1.
Figure 5 Survival After PCI and CABG
According to Kaplan-Meier analysis, there was a trend toward better
long-term survival after PCI (F-Cox test: p  0.081). Abbreviations as in Figure 1.lle in the PCI and CABG groups, but there was a trend
oward lower risk of death in the PCI group.
Improvement in LVEF with stenting but not after
ABG may be explained by restoration of physiologic
ntegrade flow in the LMCA and major vessels, lack of
erioperative reperfusion injury, and low incidence of myo-
ardial infarction. The notion of the importance of physio-
ogic antegrade flow is supported by the observations of
chmuziger and Christenson (5) after surgical restoration of
hysiologic perfusion of the LMCA by ostial patch angio-
lasty. Our prospective registry of ULMCA stenting also
howed significant improvement of systolic LV function
fter percutaneous reconstruction of the left main lumen
14). Previous surgical registries reported a high incidence of
erioperative myocardial infarction in patients with left
ain disease undergoing bypass surgery (19,20), whereas
eft main stenting has been associated with a low risk of
n-hospital death or myocardial infarction (1–4,21). This
otentially could also influence LV function in our study.
espite that, ULMCA stenosis remains one of the main
ndications for CABG because the randomized studies
onducted in the 1970s and 1980, demonstrated an advan-
age of CABG over conservative treatment with a 65%
elative reduction in mortality (21–26). Most recent studies
valuating surgical treatment for this cohort of patients
eported an in-hospital mortality rate from 1.7% to 7.0%
19–21,27), which corresponds well with our findings of an
n-hospital mortality rate of 3.8%. One-year survival of
ABG patients in the present study was 92.5%, which is
lso comparable to prior reports that showed 1-year survival
f 86% to 94% (21,22,26,28). On the other hand, a low risk
f 30-day and 1-year mortality (0% to 4%) after elective
ES implantation in ULMCA was recorded for large
roups of patients in nonrandomized studies (21,27). This
as confirmed in our study, for which there was a trend
oward better survival after PCI in 3- to 4-year follow-ups
espite selective use of DES only for small left main
eference diameters (F-Cox test: p  0.08).
Recently published nonrandomized studies comparing
ES implantation and CABG confirmed that treatment of
LMCA disease with PCI resulted in fewer early cardiac
AE and a lower or similar rate of late cardiovascular
vents (21,27). In our randomized study, we confirmed a
ower rate of 30-day MAE and MACCE in the PCI group,
s well as a similar rate of TVR and late MACCE during 3
o 4 years of follow-up. This is the first study that recorded
ll MAE (e.g., arrhythmia, heart and renal failure, excessive
leeding) to compare results of percutaneous and surgical
yocardial revascularization. Based on the current litera-
ure, those factors have a negative influence on patients’
ost-procedural progress and are routinely used to compare
ifferent surgical techniques of revascularization (29,30).
e believe that the treatment of periprocedural atrial
brillation or infections needs time and resource-consuming
herapy, not less than repeat angioplasty for restenotic
esions.
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The LE MANS Prospective Randomized Study February 5, 2008:538–45According to the new definition of in-stent thrombosis
15), there was no such late incidence in the PCI group. We
onnect this favorable outcome to selective use of DES and
ur technique of left main stenting (the provisional stenting
f a side branch and no crashed stents). The strategy of
elective use of DES was chosen because at the start of the
rial, DES with diameters of more than 3.5 mm were not
vailable. Furthermore, our prior experience demonstrated
hat when the left main reference diameter is greater than
.8 mm, the use of large-diameter BMS with high radial
trength results in very limited recoil and large minimal
uminal diameter after the procedure (14). Nonetheless, the
otal left main restenosis rate was only 9.6%. There was 1
ase of restenosis in a patient with DES (5.5%) and 4 cases
f restenosis with BMS (11.7%) with a total TVR of 9.6%.
n comparison, the TVR after ULMCA stenting in
ESEARCH/T-SEARCH registries was 6% and 23%,
espectively, after DES and BMS implantation (4,31).
The innovative strategy of this study is also related to a
igid follow-up and routine control angiography, as well as
reatment of in-stent ULMCA restenosis with repeat PCI.
n all 5 cases with renarrowing of the left main, successful
ercutaneous intervention was accomplished, resulting in
ood long-term results. Only 1 patient during the long-term
bservation underwent surgical revascularization. Similar
ood outcomes after repeat PCI for left main in-stent
estenosis have been confirmed by other authors (32).
tudy limitations. The main limitation of our study is the
elatively small number of randomized patients. This is
elated to the fact that surgical revascularization is presently
onsidered the treatment of choice for patients with severe
arrowing of ULMCA, and all current guidelines limit
ndications for left main stenting only to patients with
rotected left main stenosis or patients with high surgical
isk (33). Therefore, based on prior experience, a prespeci-
ed number of patients had to be randomized to show the
dvantage of left main stenting for improvement of LV
unction (14). Because of the size of this study, it must be
onsidered hypothesis generating rather than offering a
efinitive answer. Our results must be confirmed in a larger
andomized trial.
onclusions
ased on the results of our study, we conclude that patients
ith ULMCA disease treated with stent-supported PCI
ave favorable early outcomes in comparison with CABG.
t 1 year, LVEF improved only in the PCI group. Both
rocedures resulted in similar angina relief at 1 year and
qual risk of left main TVF. Freedom from MACCE was
omparable after more than 2 years of follow-up, and there
as a trend for better survival in the PCI group. These
ndings support the need for larger randomized trials with
linical primary end points.
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APPENDIX
chocardiography and quantitative coronary angiography core laborato-
ies were located in the Upper-Silesian Heart Center in Katowice,
oland. The Central Ethics Committee for all participating centers was
ocated at the Upper-Silesian Heart Center in Katowice, Poland. For
rimary studies, the approval of only 1 independent review board,
ppropriate for a coordinating institution, is required and acknowledged
or multicenter studies in Poland.
Seven patients were included in the study at Jagiellonian University,
rakow, Poland; 58 patients at the Medical University of Silesia in
atowice, Poland; and 40 patients in the First and Second Departments of
nvasive Cardiology, American Heart of Poland, Ustron, Poland.
